Alithea Genomics Signs Deal with Revvity to Scale Transcriptomic Profiling for Drug Discovery

Scalable transcriptomic profiling is moving closer to routine integration in early-stage drug discovery pipelines, as Alithea Genomics and Revvity have formalised a partnership to distribute MERCURIUS DRUG-seq technology through Revvity's global screening portfolio.

MERCURIUS DRUG-seq is a bulk RNA sequencing workflow designed for high-throughput compound profiling. By capturing genome-wide expression signatures across large compound libraries, the technology generates the kind of mechanistic data that supports target identification, mode-of-action characterisation, and early toxicology flagging, activities that sit upstream of IND-enabling studies and process validation commitments. Integrating this capability into Revvity's established screening infrastructure extends its reach to research organisations that may not have maintained in-house sequencing operations at this scale.

For R&D directors managing early-pipeline resource allocation, the practical read is straightforward: access to high-content transcriptomic data earlier in the discovery cycle reduces the probability of advancing compounds with poorly understood mechanisms into costly GLP and GMP-stage programmes. The partnership positions MERCURIUS DRUG-seq as a platform input rather than a specialised add-on, which has implications for how discovery teams structure their screening cascades and where AI-driven data analysis is applied.

The collaboration also reflects a broader consolidation trend in research tools, where technology developers seek established distribution networks to achieve the throughput volumes that make AI model training on transcriptomic datasets statistically meaningful. Revvity's existing relationships across pharma and biotech research sites provide that distribution infrastructure without requiring Alithea Genomics to build it independently.

No financial terms were disclosed; the timeline for full portfolio integration across Revvity's global commercial network has not been specified publicly.

The measurable checkpoint will be the rate at which MERCURIUS DRUG-seq adoption appears in published discovery programmes citing Revvity's screening services over the next two to three years.

Source: Media4Growth via Indian Pharma Post, 15 June 2026.